Active, not recruitingPhase 2NCT04784416

Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD)

Studying Twin-reversed arterial perfusion sequence

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
NYU Langone Health
Principal Investigator
Dan Iosifescu, MD, MD
NYU Langone Health and Nathan Kline Institute
Intervention
Active tPBM-2.0(device)
Enrollment
196 target
Eligibility
65-85 years · All sexes
Timeline
20212026

Study locations (3)

Collaborators

National Institutes of Health (NIH) · Alzheimer's Association · LiteCure LLC

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04784416 on ClinicalTrials.gov

Other trials for Twin-reversed arterial perfusion sequence

Additional recruiting or active studies for the same condition.

See all trials for Twin-reversed arterial perfusion sequence

← Back to all trials